Dr. Wright’s Stringer — The Founder’s Weekly Catch

THE FOUNDER’S WEEKLY CATCH

Remarkable medical claims are easy to catch. Reliable evidence takes a little more work.

Every week, Dr. Wright’s Stringer pulls interesting medical, longevity, peptide, biotechnology, and regenerative-medicine stories from the fast-moving current of public attention.

DR. WRIGHT’S STRINGER | November 3, 2026

Dementia: Understanding Today. Exploring Tomorrow.

Dementia: Understanding Today, Exploring Tomorrow. An older adult and loved one walking together toward warm light, with the Founders emblem.

FOUNDERS INSTITUTE OF MEDICINE & EDUCATION
Wright’s Stringer • Reader’s Net • November 3, 2026

Alzheimer’s & Lewy body dementia

What they are. What helps. Where hope is moving.

Dementia means problems with memory or thinking that make everyday life harder to manage without help. It is a name for a group of problems, not one disease. It is not a normal part of aging. Alzheimer’s disease and Lewy body disease are two causes. Some people have both. [1–4]

The quick distinction: Alzheimer’s often starts with trouble remembering new information. A person with Lewy body dementia may have good and bad periods of attention, see things that are not there, act out dreams, or develop slow, stiff movements. Memory problems can occur in either disease. One symptom alone cannot tell us which disease a person has. [1,3]

Typical pattern Alzheimer’s Dementia with Lewy bodies
Early clues Repeating questions; forgetting recent events Attention comes and goes; trouble judging space; seeing things not there
Other clues Trouble finding words or finding the way Acting out dreams; stiffness; slow movement; falls; blood-pressure or bowel problems
Protein changes in the brain Amyloid-beta buildup and tangled tau Alpha-synuclein buildup; Alzheimer’s changes may also be present
What treatment offers Symptom relief; some medicines can slow early illness Symptom relief; medicines to slow the disease are still being tested

Why the type matters: Knowing the cause helps doctors choose medicines, explain what to expect and find suitable research studies. A memory problem needs a careful check rather than an automatic label of Alzheimer’s. [1,3,5]

Wright’s Stringer • Reader’s Net research review • Evidence checked November 3, 2026. U.S. approval status unless stated otherwise. This article explains selected research; it is not a complete review of every study or a personal treatment plan.

What is happening
inside the brain?

Alzheimer’s: buildup and damage

In Alzheimer’s, a protein called amyloid-beta builds up between brain cells. Another protein, tau, forms tangles inside them. Cells have trouble communicating, some cells die, and the brain gradually loses abilities. Removing amyloid can help slow the illness in some people, but it cannot undo all the damage. [2,7]

Researchers are also studying inflammation, damaged blood vessels and problems with the brain’s waste-removal systems. Genes and aging affect how well the brain can cope. Several processes appear to work together, which helps explain why one medicine is unlikely to solve the whole problem. [2]

Lewy body disease: a different protein problem

Lewy body disease involves a protein called alpha-synuclein. This protein normally helps brain cells communicate. In this disease, it folds into the wrong shape and builds up. Researchers are studying how it damages cells and overwhelms their cleanup systems. Changes in brain chemicals help explain the effects on thinking, movement, sleep and behavior. Scientists do not yet know exactly what starts the disease. [1,3]

Lewy body dementia includes dementia with Lewy bodies (DLB) and Parkinson’s disease dementia. The names depend largely on timing. Doctors usually call it DLB when thinking problems begin before, or within about a year of, Parkinson-like movement problems. When someone has had Parkinson’s disease for longer before dementia begins, doctors call it Parkinson’s disease dementia. The two are closely related. [1,3]

More than one cause can be present

A person can have the protein changes of both Alzheimer’s and Lewy body disease. Blood-vessel damage can add to the problem. This helps explain why people with the same diagnosis may have different symptoms. Tests that identify these changes may eventually help doctors choose treatments more precisely. [3,4]

The research goal: Find the disease early, identify what is driving it and protect brain cells before too much damage occurs. Repairing damage that has already happened is harder. That is why researchers are testing whether treatment before symptoms can help. [2,15,16]

A better diagnosis
opens better choices.

A good evaluation includes talking with the patient and someone who knows them well, checking memory and thinking, examining movement and reviewing medicines. Blood tests and brain scans may help. Doctors also look for other problems, such as poor sleep or medication side effects, that may make thinking worse. No test should be read without considering the whole person. [1,3,5]

Blood tests can help, but do not tell the whole story

In May 2025, the FDA cleared the first blood test to help diagnose Alzheimer’s: the Lumipulse test. It measures two proteins to help estimate whether amyloid has built up in the brain. It is intended for people aged 55 and older who already have signs of memory or thinking trouble and are being evaluated in specialized care. It cannot diagnose Alzheimer’s by itself and is not a general screening test for people without symptoms. [6]

When checking for DLB, doctors ask about seeing things that are not there, major changes in alertness, acting out dreams and movement problems. Sleep testing or certain scans may help. New tests for alpha-synuclein are promising, but finding a protein does not explain every symptom or replace a careful medical evaluation. [1,3,4]

What families can bring to the visit

Bring a list of medicines and supplements, plus real examples of changes at home. Write down when problems with memory, walking, attention, sleep or seeing things began. Did movement problems start years before memory problems? What can the person still do without help? A clear timeline helps the doctor put the pieces together. [1,3]

Two practical safety points

Sudden confusion needs attention. A rapid change may be caused by a new medical problem. Do not assume it is simply the dementia getting worse; seek prompt medical assessment. [1]

Tell the medical team about possible Lewy body dementia before medicines for hallucinations are given. Some antipsychotic medicines can cause severe sleepiness, much worse movement or other dangerous reactions. Haloperidol is a particular concern. Seeing something that is not there does not always require medicine; the doctor should consider how distressing or dangerous the symptom is. [10,11]

What treatment
can do today

Helping people feel and function better

For Alzheimer’s, medicines such as donepezil, rivastigmine and galantamine may help memory and thinking symptoms. Memantine is used in moderate to severe disease. These medicines do not cure Alzheimer’s. Good care also addresses sleep, mood, daily routines, safety and the needs of family caregivers. [5]

For Lewy body dementia, some of the same memory medicines may help thinking and sometimes hallucinations. Results with memantine are mixed. Levodopa may ease stiffness or slow movement, but can make hallucinations or confusion worse. Sleep, constipation, falls and blood-pressure problems also need care. Therapy to improve movement and daily activities can help, along with caregiver support. No approved medicine has been shown to slow the underlying LBD illness. [9,10]

Newer Alzheimer’s medicines can slow worsening

Lecanemab (Leqembi) and donanemab (Kisunla) can slow worsening in some people with early Alzheimer’s. Treatment requires evidence of amyloid buildup and either mild dementia or earlier thinking problems called mild cognitive impairment. These medicines are not for every stage or type of dementia. We cannot assume they will help someone whose main illness is DLB. [5,7,8]

What does “slowing” mean? In an 18-month lecanemab study, researchers used a scale that measures thinking and daily abilities. Scores worsened by an average of 1.21 points with the medicine and 1.66 points with a dummy treatment, on a 0–18 scale. That difference is often described as 27% less decline. Both groups still got worse on average. It does not mean that patients regained 27% of their memory. [7]

Donanemab also slowed worsening in its study. Because the studies were different, their percentages do not tell us which drug is better. Patients and families need to discuss the likely benefit, treatment visits and risks with a specialist. [7,8]

The main safety concern is ARIA, the name for brain swelling or bleeding that can appear on scans. It can occasionally be serious or fatal. Treatment involves MRI scans and a review of medicines, bleeding risks and genetic risk factors such as APOE. In July 2026, the FDA approved starting Leqembi with injections under the skin. Easier delivery does not remove these risks or make it a cure. [8,12,13]

What researchers
are trying next

1 / Get more medicine into the brain

Trontinemab uses a “brain shuttle” to help an amyloid-targeting medicine get past the brain’s protective barrier. Early findings suggest it can remove amyloid. Larger studies must show whether it also helps people keep their thinking and daily abilities, with acceptable risks. The large TRONTIER 1 study is underway but is not taking new participants (NCT07169578). Its main results are expected after the study’s estimated primary finish in February 2028. Benefit in this large study has not yet been proven. [14,15]

2 / Start before symptoms

The AHEAD 3-45 studies ask whether lecanemab can help people who have amyloid changes but no noticeable thinking problems yet. These studies are underway but are not taking new participants. Their main study period is expected to finish in December 2028 (NCT04468659). Preventive treatment with lecanemab is still being tested. [16]

A newer study, PrevenTRON, is taking participants according to its October 13, 2026 update (NCT07717411). It tests trontinemab in adults aged 55–80 who have no thinking problems but meet certain blood-test and health requirements. Researchers plan to enroll 1,600 people and follow them for years; the main study period is expected to finish in 2032. The question is whether treatment can delay symptoms. We do not have the answer yet. [17]

3 / Make less of the tau protein

Diranersen (BIIB080) aims to reduce how much tau protein the body makes. It is given into the fluid around the spinal cord. It works on the instructions used to make protein; it does not change a person’s DNA. The CELIA study did not meet its main goal of showing how different doses affected decline. The company reported lower tau levels and encouraging results in some additional analyses. Those findings need confirmation. Biogen has announced plans for a larger follow-up study. [18,19,31]

The negative results matter too

The large EVOKE and EVOKE+ studies found that oral semaglutide did not slow early Alzheimer’s over about two years. A treatment can improve a blood test or sound promising in theory without helping memory or daily life. Unsuccessful studies help researchers decide what to try next. [20]

Study status checked November 3, 2026. A study may be taking participants overall but have no openings nearby. Finish dates can change. A study finishing does not mean a medicine will be approved.

New treatments being tested
for Lewy body dementia

Zervimesine / CT1812: protecting brain-cell connections

This experimental pill aims to protect connections between brain cells from harmful protein buildup. In the published SHIMMER study, 130 people with DLB were assigned by chance to medicine or a dummy treatment for 26 weeks. The main goal was to check safety and how well people tolerated it. Some other findings were encouraging, but this small, short study cannot prove that the drug slows the disease over time. [21]

After meeting with the FDA, the company described plans for a larger DLB study. This does not mean the medicine has been approved. SHIMMER itself is finished (NCT05225415). Anyone interested should ask about follow-up studies rather than expect to join SHIMMER. [22,23]

Ambroxol: helping cells clear waste

Ambroxol is being studied to see whether it can help the cell’s recycling system work better and handle abnormal alpha-synuclein. The ANeED study is listed as taking participants in Norway (NCT04588285). It plans to enroll 180 people, with the main study period expected to finish in September 2027. We do not yet know whether it helps DLB. The research uses doses and medical monitoring very different from ordinary cough-medicine use. Do not try to copy the treatment yourself. [24,25]

Neflamapimod: more testing is needed

An early report from RewinD-LB, involving 159 people, was released in August 2026 before independent experts had reviewed it. It did not show a clear benefit on the main measure of thinking and daily function, or on other clinical and blood-test measures. Findings in smaller groups may help shape another study, but they do not prove the medicine works for people with DLB overall. [26]

What would be a meaningful breakthrough?

A meaningful breakthrough would help people think, function or manage major symptoms better—or keep those abilities longer—with risks they can accept. Researchers need to show the benefit reliably in a well-designed study. They also need to account for how much LBD varies and how often Alzheimer’s changes occur alongside it. [3,4,21]

These are examples, not every available study. A memory clinic can help find studies that fit the person’s diagnosis, stage of illness, health and location. Study links are in the sources.

AI can shorten the search.
People must prove the benefit.

AI is useful because dementia research involves enormous amounts of genetic, protein, imaging, chemical and clinical data. It can help identify patterns and rank experiments that humans could not inspect one by one. It does not turn a plausible mechanism into a proven treatment. [27–30]

Two concrete examples of progress

Alzheimer’s and cellular recycling: A 2026 Nature Biomedical Engineering study described an AI-guided drug-discovery system that searched for compounds promoting autophagy, the process cells use to recycle material. The work included brain-penetration and other drug-property predictions. Lead compounds reduced pathological aggregates and improved memory-related outcomes in experimental models. These were worm and mouse results, not evidence of restored memory in people with Alzheimer’s. [27]

Alpha-synuclein aggregation: A Nature Chemical Biology study used iterative machine learning and laboratory experiments to find more potent small-molecule inhibitors of alpha-synuclein aggregation. This is relevant to the biology shared by Parkinson’s and Lewy body diseases. Laboratory potency does not establish that a medicine will enter the human brain safely or slow dementia. [28]

Where AI may make the biggest practical difference

Choose better targets: Combine genetics and molecular data to identify pathways that may drive disease, then test whether changing them helps. Design better molecules: Prioritize candidates likely to reach the brain, bind the intended target and avoid toxicity. Run more informative trials: Identify biological subgroups, improve trial matching and detect change more consistently. Support recognition: Help interpret clinical and imaging patterns while clinicians check alternative explanations. [29,30]

Every proposed benefit still needs reliable data, independent validation and careful human studies. Biased datasets can produce misleading predictions. Better diagnosis alone is not a cure, and an AI-generated molecule can fail like any other candidate. [30]

Hope that can stand up to scrutiny

The most credible path is earlier detection, more precise biological classification, safer medicines and eventually combinations that address several drivers of injury. Alzheimer’s has crossed an important threshold: selected treatments can modestly slow decline. LBD research is expanding, but has not yet established comparable disease slowing. AI may speed the journey; neither disease has a proven AI-developed cure today. [5,9,27–30]

For the next visit: What diagnosis best fits? Is mixed disease likely? Would a biomarker change care? Are symptom medicines optimized? Is an approved disease-slowing treatment appropriate? Which trial fits this person now?

Where can families
find help and studies?

You do not need to sort through the research alone. These trusted starting points can help people with dementia and their families learn about the illness and look for studies.

Alzheimer’s Association: a simple place to start

TrialMatch is a free service that helps match people with Alzheimer’s or another dementia, caregivers and healthy volunteers with research studies. It includes treatment, diagnosis, care and prevention research. Visit alz.org/trialmatch. For help, call 800-272-3900 or email TrialMatch@alz.org.

For disease information and family support, visit alz.org. The same number, 800-272-3900, reaches the Association’s 24/7 Helpline. It is a useful first step if you would rather speak with someone.

Lewy body dementia: focused information and research

The Lewy Body Dementia Association provides information about symptoms, treatment and caregiving at lbda.org. To explore research opportunities, visit lbda.org/research/clinical-studies. Its Lewy Trial Tracker offers study updates and contact information: lbda.org/lewy-trial-tracker.

Government resources: information and study searches

The National Institute on Aging explains dementia and offers guidance on finding research. Start at nia.nih.gov/alzheimers/clinical-trials for its trial-finder links. For a plain-language explanation of Lewy body dementia, see NINDS: Lewy Body Dementia.

For a broader search in the U.S. and other countries, use ClinicalTrials.gov. Enter “Alzheimer disease” or “dementia with Lewy bodies,” add your location and choose Recruiting. Read what the study tests and use the listed contact to ask whether it fits.

Before joining, ask these questions

Is this a treatment study or a study that only collects information? Does the diagnosis and stage fit? What are the possible benefits and risks? How many visits are needed? Is a caregiver or study partner required? Can any visits be remote, and is travel help available? The study team confirms eligibility; a website match does not guarantee enrollment or benefit.

Links and contact information checked November 3, 2026. Review any study with the treating clinician. Participation is voluntary; taking part in research does not guarantee a better treatment outcome.

Sources & trial records

Numbered references support the preceding text. Links are clickable. Primary papers, regulators and trial registries are prioritized; sponsor announcements and the preprint are labeled. All accessed November 3, 2026.

[1] NIA. What is Lewy body dementia? Open source

[2] NIA. What happens to the brain in Alzheimer’s disease? Open source

[3] McKeith et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report. Neurology, 2017. Open source

[4] NINDS. Lewy Body Dementia Biomarkers. Open source

[5] NIA. How is Alzheimer’s disease treated? Open source

[6] FDA. First blood test used in diagnosing Alzheimer’s disease. May 16, 2025. Open source

[7] van Dyck et al. Lecanemab in Early Alzheimer’s Disease. NEJM, 2023. Open source

[8] FDA. Kisunla approval and trial results. July 2, 2024. Open source

[9] NINDS. Lewy Body Dementia. Open source

[10] Lewy Body Dementia Association. Treatment options. Open source

[11] Lewy Body Dementia Association. Emergency room treatment of psychosis. Open source

[12] Leqembi prescribing information. Updated July 21, 2026. Open source

[13] FDA. Subcutaneous Leqembi starting regimen. July 13, 2026. Open source

[14] Genentech. Trontinemab development program. Sponsor source. Open source

[15] ClinicalTrials.gov. TRONTIER 1: NCT07169578. Record updated September 25, 2026. Open source

Sources & trial records

Numbered references support the preceding text. Links are clickable. Primary papers, regulators and trial registries are prioritized; sponsor announcements and the preprint are labeled. All accessed November 3, 2026.

[16] ClinicalTrials.gov. AHEAD 3-45: NCT04468659. Record updated June 4, 2026. Open source

[17] ClinicalTrials.gov. PrevenTRON: NCT07717411. Record updated October 13, 2026. Open source

[18] Biogen. CELIA phase 2 primary findings. May 14, 2026. Sponsor report. Open source

[19] Biogen. Expanded CELIA analyses, July 14, 2026; phase 3 planning in October filing. Sponsor sources. Open source

[20] EVOKE / EVOKE+ randomized trials of semaglutide in early Alzheimer’s. Lancet, 2026. PMID 41865758. Open source

[21] SHIMMER randomized phase 2 trial of CT1812 in DLB. Alzheimer’s & Dementia, December 19, 2025. Open source

[22] Cognition Therapeutics. FDA meeting and planned DLB program. May 21, 2026. Sponsor report. Open source

[23] ClinicalTrials.gov. SHIMMER: NCT05225415. Completed; results posted. Open source

[24] ANeED ambroxol DLB randomized trial protocol. 2023. Open source

[25] ClinicalTrials.gov. ANeED: NCT04588285. Record updated May 5, 2026. Open source

[26] RewinD-LB neflamapimod trial. Research Square preprint, August 14, 2026. Not peer reviewed. Open source

[27] AI-guided discovery of autophagy-enhancing compounds for Alzheimer’s models. Nature Biomedical Engineering, 2026. Open source

[28] Iterative machine learning to discover alpha-synuclein aggregation inhibitors. Nature Chemical Biology, 2024. Open source

[29] NIH. 2026 Alzheimer’s disease and related dementias research progress report. Open source

[30] AI in drug discovery: perspective on clinical evidence. Nature Reviews Drug Discovery, August 2026. Open source

[31] Biogen. October 2026 SEC filing: diranersen confirmatory phase 3 planning. Open source

DR. WRIGHT’S STRINGER
Catching Tomorrow’s Medicine Today

AI Can Design a Drug in Days. So Why Does It Still Take Years to Reach a Patient?

AI can design a drug in days — Dr. Wright’s Stringer

Imagine asking a computer to help identify a biological target, generate new molecular structures, predict which candidates might bind, estimate useful properties, reject weak candidates, and hand scientists a shortlist.

That sounds like science fiction. It is increasingly becoming pharmaceutical research.

But there is an important catch: AI can accelerate the search for a drug. It cannot yet accelerate biology at the same speed.

What AI is actually changing

AI is already being used in target identification, protein-structure prediction, virtual screening, de novo molecule generation, lead optimization, ADME and toxicity prediction, literature analysis, and parts of clinical-trial planning.

The clearest gains so far are at the front end of discovery: searching enormous chemical spaces and prioritizing candidates before scientists spend time and money synthesizing and testing them.

The reality check

A molecule that looks excellent computationally can fail in a cell. A compound that works in animals can fail in humans. A drug can hit its intended target and still prove too toxic—or simply fail to improve the disease.

That is why “designed in days” does not mean “medicine in days.” Chemistry, preclinical validation, toxicology, manufacturing, Phase I, Phase II, Phase III, and regulatory review remain formidable gates.

One of the field’s biggest tests: rentosertib

Insilico Medicine’s rentosertib, being developed for idiopathic pulmonary fibrosis, is an important real-world test. AI was used in identifying the TNIK target and designing the molecule. After early clinical development and Phase II testing, Insilico announced advancement into Phase III in 2026.

That milestone matters because it moves the AI-drug story beyond attractive computer models and into the place where every medicine ultimately has to prove itself: real patients.

The bottleneck may be shifting

The old question was often: Which molecule should we try?

AI is getting dramatically better at narrowing that search.

The next question is harder: Was the prediction biologically correct?

And biology still gets the final vote.

What comes next: AI research partners

The next evolution goes beyond one algorithm generating one molecule. Researchers are connecting AI systems with scientific literature, molecular-design programs, laboratory automation, biological assays, experimental databases, and clinical-development planning.

The long-term vision is sometimes described as “prompt-to-drug”: AI helps coordinate target discovery, chemistry, synthesis, testing, interpretation, and iteration.

That does not mean scientists disappear. It could mean scientists gain a far more powerful starting point—and the ability to explore parts of chemical and biological space that humans could never search manually.

THE STRINGER

CLAIM: “AI can design a drug in days.”

WHAT THE EVIDENCE SAYS: Some portions of early molecular design and candidate generation can indeed be compressed dramatically.

CLAIM: “Making one still takes months.”

WHAT THE EVIDENCE SAYS: Often much longer. Synthesis, validation, preclinical work, clinical trials, manufacturing, and regulatory review can still require years.

WHAT HAS CHANGED: AI is rapidly shrinking parts of the discovery search.

WHAT HASN’T: Patient safety and clinical proof remain the gatekeepers.

What Founders Is Watching

The first AI-discovered drug to receive full regulatory approval; whether AI-generated candidates fail less often in clinical trials; AI-connected robotic laboratories; and whether these systems uncover treatments humans would never have thought to build.

The real revolution may not simply be faster drug development. It may be access to medicines hidden in chemical spaces we have never been able to explore.

— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education

Sources: Nature Reviews Drug Discovery (2026): AI drug discovery perspective | Insilico Medicine: rentosertib Phase III | Insilico Medicine: rentosertib program | Drug Discovery Today (2026): AI agents in drug discovery

Dr. Wright’s Stringer explores emerging medical research and technology. This article is educational and is not medical advice. Investigational drugs discussed here are not presented as established treatments.

DR. WRIGHT’S STRINGER
Catching Tomorrow’s Medicine Today

Living With Lupus?

Could Exosomes Open a New Door?

Living with lupus? Could exosomes open a new door? Founders Stringer editorial illustration

Tired of the fatigue, muscle pain, weakness, and unpredictable flares?

Tired of explaining why you look well—even when you feel anything but well?

Ever wonder how much longer it will be before better treatments—or perhaps even a cure—are finally within reach?

Living with lupus can mean waking up each morning without knowing what kind of day your body will allow you to have.

A good day may be followed by crushing exhaustion. Aching muscles and joints can make ordinary activities feel overwhelming. Concentration may disappear. Symptoms can improve, return, or change without warning.

And because so much of lupus can be invisible, friends, coworkers, and even family members may not fully understand what you are carrying.

But researchers are continuing to look for better answers—and one emerging area of study is especially fascinating.

What Are Exosomes?

Every cell in the body needs a way to communicate.

One way cells exchange information is through extremely small packages called extracellular vesicles. Exosomes are one type of these microscopic messengers.

They can carry proteins, genetic instructions, and other biological signals from one cell to another. Those messages may influence inflammation, immune activity, healing, and how surrounding cells behave.

Researchers are now asking an important question:

Could these cellular messages eventually help us redirect an immune system that has mistakenly begun attacking the body?

Why Could This Matter in Lupus?

Lupus is an autoimmune disease. Instead of protecting the body only from outside threats, the immune system can become misdirected and attack the body’s own tissues.

That can affect the joints, muscles, skin, blood vessels, kidneys, heart, lungs, nervous system, and other organs.

Exosomes appear to participate in this complicated immune conversation. Some may carry signals that contribute to inflammation. Others—particularly extracellular vesicles produced by certain stem cells—are being studied for their potential to encourage a calmer, more balanced immune response.

In laboratory and animal research, scientists have reported effects involving:

  • The regulation of inflammatory signals
  • Communication between immune cells
  • T-cell and B-cell activity
  • Macrophages that help clear damaged or dying cells
  • Biological pathways involved in lupus-related kidney injury
  • The restoration of healthier immune balance

That does not mean that an approved exosome treatment for lupus has arrived.

It means researchers may have discovered another way to listen to—and perhaps someday influence—the messages passing between immune cells.

A New Way of Thinking

Most lupus treatments work by suppressing or modifying parts of the immune response.

Exosome research raises a different possibility.

What if future treatments could deliver carefully selected biological messages that help immune cells behave differently?

What if scientists could quiet damaging inflammation without simply shutting down broad portions of the immune system?

What if the body’s own communication system could eventually become part of the treatment?

Those questions have not yet been answered—but they are now being seriously investigated.

And that is where hope begins.

What About Peptides?

Peptides are another way cells and tissues communicate. These small chains of amino acids can participate in inflammation, immune signaling, tissue repair, metabolism, and many other biological processes.

The Founders Peptide Library contains physician-developed educational monographs examining peptides connected with these pathways.

Readers interested in lupus may wish to explore our materials on peptides being investigated in relation to inflammation and immune regulation, including KPV, as well as other research compounds associated with tissue response and recovery.

These peptides are not presented as proven treatments or cures for lupus. The library is designed to help readers understand the emerging biology, the research, the unanswered questions, and the possibilities scientists are exploring.

EXPLORE THE PEPTIDE LIBRARY

THE STRINGER

Exosomes are not an established lupus treatment—but this story is about more than whether a treatment is available today.

It is about where medicine may be going next.

For people who have spent years living between flares, appointments, medication changes, and unanswered questions, progress can feel painfully slow. Yet research is moving forward in ways that were difficult to imagine only a generation ago.

Scientists are learning more about how immune cells communicate, why those messages sometimes go wrong, and whether healthier instructions might someday be delivered back into the system.

Every treatment we rely on today began with someone asking a question that medicine could not yet answer.

Could exosomes help open a new door for people living with lupus?

We do not know yet.

But the door is being studied—and Founders will continue watching it.

Want Us to Keep You Updated?

You should not have to search through medical journals and internet headlines to learn when something important changes.

Use the “Stay Informed” email signup below. We will regularly share meaningful developments involving new lupus treatments and medications, emerging exosome research, clinical trials and enrollment opportunities, and immune-regulation discoveries—explained in language you can actually understand.

Stay informed. Keep asking questions. And do not let go of hope.

The next meaningful lupus breakthrough may already be taking shape.

Let’s follow it together.

— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education

Sources: MSC-derived exosome research in systemic lupus erythematosus | Extracellular vesicles and immune responses in experimental lupus nephritis | Review of exosome research in systemic lupus erythematosus | Review of exosomes and microRNAs in lupus research

Dr. Wright’s Stringer explores emerging medical research and technology. This article is educational and is not medical advice. Exosome-based therapy is not an established or approved treatment for lupus; patients should discuss treatment decisions with qualified healthcare professionals.

Caught Something Interesting?

Send us the product, headline, advertisement, video, or medical claim you would like Founders to investigate.

SUBMIT YOUR CATCH

WRIGHT’S STRINGER ARCHIVE

Curiosity is welcome. Evidence decides what stays on the stringer.

Educational information only. Not medical advice. Research summaries may change as new evidence becomes available.

What We Track

Peptides, regenerative medicine, genetics, longevity science, and emerging therapeutics with the potential to change care.

How We Evaluate

We review the quality of the evidence, potential benefits, known risks, unaswered questions, and where the science stands today.

What You Get

Clear, concise evidence summaries designed to help you understand what matters, what is changing and what deserves your attention.

What Navigator Covers

Regenerative Medicine & Peptides

Evidence, safety, outcomes, and evolving research in regenerative therapies and peptide science.

Genetics & Longevity

Research in genetics, cellular aging, longevity, and the technologies shaping the future of human heealth.

Emerging Therapeutics

Promising therapies and technologies-from early research to clinical translation-with clear attention to evidence, risk, and uncertainty.

Stay Ahead of Changing Medicine

Evidence-based insights for clinicians and curious minds who want to understand where medicine is going not just where it has been.

Reader’s Net Archive Join Navigator - $24.95/month